Declaración de PrivacidadTérminos de UsoEntrar Registro
 
HomeCompanyBiotechnologyParticipating BusinessesBusiness ModelInvestment ManagementPress RoomContact
TCD PHARMA

 

  • Formed: 2005, investigation from 1989 

  • Scientific source: Patents and investigation of Dr. J.C. Lacal (IIB-CSIC-UAM) 

  • First lines: 

    • 1. Post-surgery prognostic marker in non-small cell lung carcinoma (NSCLC)

    • 2. Therapy products: various  families of enzyme activity inhibitors and with anti-tumour activity

  • Value proposition: New and personalised approach in the treatment of cancer

  • Demographic data: The four types of cancer with proven ChoK tumoural activity make up almost 50% of new cancer cases in the developed world and China, with almost 4 million new cases each year

  • Intellectual Property: 1 Patent and 6 applications

  • Development Stage

    • Therapy: compound TCD 717 in preclinal stage (animals), compound TCD 973 in laboratory trials
    • Antibodies: available for licence and possible co-development
    • Diagnostics: Lung kit (validated)/bladder kit in development
TCD PHARMA

Platform for diagnosis and therapy in cancer.

Platform based on the knowledge of the activity, inhibitors, and metabolic activity of the Choline Kinase  (ChoK) enzyme and its role in different types of tumours present in common cancers: lung, breast, bladder, colorectal, and pancreatic.